[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-ulcer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-ulcer":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,52,77,106,133,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100616957","phase-4-esomeprazole-plus-sucralfate-for-post-esd-ulcer-healing-100616957",false,"NCT07312370","Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","Intravenous Esomeprazole Combined With Sucralfate Suspension for Ulcer Healing and Complication Prevention After Gastric Endoscopic Submucosal Dissection: A Prospective, Randomized, Controlled Trial","Inclusion Criteria:\n\n1. Age 18-80 years, male or female\n2. Diagnosed with early gastric cancer or high-grade intraepithelial neoplasia planned for gastric ESD\n3. Lesion location: Gastric corpus, antrum, or angle (cardiac lesions may be included but will require subgroup analysis)\n4. Successful en bloc resection achieved by ESD\n5. Post-ESD artificial ulcer diameter ≥2 cm\n6. Complete coagulation of all visible vessels during ESD procedure\n7. ECOG performance status 0-1\n8. Able to comply with follow-up visits and endoscopic examinations\n9. Voluntary participation with written informed consent\n\nExclusion Criteria:\n\n1. Previous gastric surgery history\n2. Active peptic ulcer disease (confirmed by pre-ESD endoscopy) within 1 month\n3. Recent upper gastrointestinal bleeding (within 1 month, excluding tumor-related bleeding)\n4. Severe heart, liver, or kidney dysfunction (Child-Pugh class C, NYHA class III-IV, or CKD stage 4-5)\n5. Coagulation disorders (INR \\>1.5 or platelet count \\\u003C50×10⁹\u002FL)\n6. Uncontrolled diabetes (HbA1c \\>9%)\n7. Known allergy or hypersensitivity to PPIs or sucralfate\n8. Use of PPIs, H2 receptor antagonists, or mucosal protective agents within 2 weeks prior to ESD\n9. Long-term anticoagulant therapy that cannot be discontinued (e.g., warfarin, direct oral anticoagulants)\n10. Long-term NSAIDs or aspirin (\\>100mg\u002Fday) that cannot be discontinued\n11. Unsuccessful complete (en bloc) resection (piecemeal resection)\n12. Intraoperative perforation\n13. Uncontrolled active bleeding during ESD\n14. Pregnancy or lactation\n15. Women of childbearing potential not using adequate contraception\n16. Concurrent participation in another clinical trial\n17. Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation","ALL","18 Years","80 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Endoscopic submucosal dissection (ESD) is an established treatment for early gastric cancer and precancerous lesions. Post-ESD artificial ulcers may lead to complications including delayed bleeding (3-15%) and prolonged healing. Current guidelines recommend high-dose proton pump inhibitors (PPIs), but evidence for additional mucosal protective agents remains limited.\n\nThis study aims to evaluate whether combining sucralfate suspension with standard intravenous esomeprazole therapy improves ulcer healing and reduces complications after gastric ESD compared to esomeprazole alone.\n\nThis is a prospective, randomized, controlled, outcome-assessor-blinded trial. A total of 120 patients undergoing gastric ESD will be randomly assigned 1:1 to receive either:\n\n* Intervention group: Intravenous esomeprazole 40mg twice daily (3 days) followed by oral esomeprazole 40mg once daily PLUS sucralfate suspension 1g twice daily for 8 weeks\n* Control group: Intravenous esomeprazole 40mg twice daily (3 days) followed by oral esomeprazole 40mg once daily for 8 weeks The primary outcome is ulcer reduction rate at 4 weeks post-ESD, assessed by endoscopy. Secondary outcomes include complete ulcer healing rate at 8 weeks, delayed bleeding rate, symptom scores, and safety parameters.\n\nThis study will provide high-quality evidence regarding the role of sucralfate as an adjunctive therapy for post-ESD ulcer management and may inform future clinical guidelines.",[27,28,29,30,31],"Early Gastric Cancer","Gastric Dysplasia","Gastric Neoplasms","Peptic Ulcer With Haemorrhage","Gastric Ulcer",[33,34,35,36,37,38],"Endoscopic Submucosal Dissection","Gastric Cancer","Ulcer Healing","Proton Pump Inhibitor","Post-ESD Ulcer","Early Gastric Neoplasm","NOT_YET_RECRUITING","2026-03-19",{"date":42,"type":43},"2026-03-23","ACTUAL",{"date":45,"type":21},"2026-04-20",{"date":47,"type":21},"2026-12-30",{"name":49,"class":50},"LanZhou University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":51},"100622562","phase-1-compare-and-evaluate-the-safety-and-pk-data-of-a-single-dose-administration-of-ad-115a-or-ad-1151-100622562","NCT07385235","Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'","A Randomized, Open-label, Single-dose, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-115A and the Administration of AD-1151 for Healthy Subjects in Fasting State","Inclusion Criteria:\n\n* The Age equal to or greater than 19 in healthy volunteers at the time of screening visit\n* Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n\nExclusion Criteria:\n\n* Individuals who have taken drugs that induce (e.g., barbiturates) or inhibit drug-metabolizing enzymes within 30 days prior to the start of the study (first dosing day), or have taken drugs that may affect this study within 10 days prior to the start of the study (first dosing day)\n* Other exclusions applied","19 Years",{"count":61,"type":21},46,[63],"PHASE1","The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.",[31],"RECRUITING","2026-02-09",{"date":69,"type":43},"2026-02-11",{"date":71,"type":43},"2026-01-27",{"date":73,"type":21},"2026-03-16",{"name":75,"class":76},"Addpharma Inc.","INDUSTRY",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":51},"100595477","a-cohort-study-of-mobile-capsule-gastroscopy-for-gastric-pathologies-screening-100595477","NCT07032961","A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening","Screening for Gastric Pathologies in Elderly and High-Risk Populations Using a Mobile Capsule Gastroscopy System: a Prospective, Multicenter, Population Based Cohort Study","Inclusion Criteria:\n\n1.Provision of written informed consent; 2.Participants of the 'Gastric Pathologies Screening Programme for the Elderly and High Risk Groups in Guangzhou Municipality', the following are the criteria for inclusion in this public welfare programme:\n\n1. Elderly cohort: Permanent residents of Guangzhou aged ≥60 years who have not undergone specialized gastric disease screening in the past three years;\n2. Or high-risk cohort: Individuals aged ≥45 years who meet at least one of the following risk criteria:\n\n   1. History of Helicobacter pylori infection (positive ¹³C\u002F¹⁴C urea breath test);\n   2. Prior diagnosis of chronic atrophic gastritis, gastric ulcer, neoplastic gastric polyps, hypertrophic gastritis, or pernicious anemia;\n   3. Family history of gastric cancer (first-degree relative with a confirmed diagnosis);\n   4. Long-term high-salt diet, smoking history (≥20 pack-years), or heavy alcohol consumption (100 mL of distilled spirits\u002Fday).\n\nExclusion Criteria:\n\n1. Not considered by the investigator to be suitable for participation in this study.\n2. Meets the exclusion criteria of the Public Welfare Programme. Individuals will be excluded if they meet any of the following conditions:\n\n(1)Known allergy to medical polymer materials; (2)Psychiatric disorders that interfere with procedural cooperation; (3)Pregnancy or lactation; (4)Severe systemic comorbidities (e.g., cardiovascular, respiratory, neurological diseases) affecting examination tolerance; (5)Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or gastrointestinal diverticulosis; (6)Known or suspected gastrointestinal malformations, obstructions, strictures, or fistulas; (7)Clinically significant dysphagia; (8)Acute abdominal symptoms (e.g., pain, vomiting, suspected bowel obstruction, or severe constipation); (9)History of major gastrointestinal surgery (e.g., esophagogastrostomy, gastrojejunostomy); (10)Physical debilitation precludes postural changes or concurrent severe illness; (11)Medically ineligible for abdominal procedures or refusal to undergo them; (12)Deemed unsuitable for MCG by the investigator; (13)Refusal to provide informed consent; (14)Any other condition judged by the investigator to make the individual unsuitable for study participation.",true,"45 Years",{"count":87,"type":21},10000,"OBSERVATIONAL","The goal of this is to learn about the effectiveness and feasibility of a novel AI- assisted Mobile Capsule Gastroscopy (MCG) system for detecting gastric pathologies in elderly and high-risk populations.\n\nThe main question it aims to answer is:\n\nCan MCG effectively detect gastric pathologies, including common gastric diseases, gastric cancer, and precancerous lesions, in elderly and high-risk individuals at community health centers?\n\nParticipants will:\n\nEpidemiological, diagnostic, and post-MCG follow-up data generated during participants' involvement in the gastric pathologies public screening program will be collected.",[91,28,31,34,92],"Gastritis","Gastric Mass",[94,95,96],"Capsule Endoscopy","Prospective Study","screening","2025-07-03",{"date":99,"type":43},"2025-07-04",{"date":101,"type":43},"2025-06-24",{"date":103,"type":21},"2030-10-31",{"name":105,"class":50},"Nanfang Hospital, Southern Medical University",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},"100581291","capsule-gastric-endoscopy-for-gastric-disease-screening-in-simulated-home-scenarios-100581291","NCT06848400","Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios","A Multicenter, Prospective Study of Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios","Inclusion criteria\n\n1. Aged 18 years or older.\n2. Individuals meeting the following criteria:\n\n   i. Healthy volunteers; ii. Suspected presence of gastrointestinal diseases, with one or more of the following clinical symptoms: abdominal pain, nausea, vomiting, hematemesis, black or bloody stools, loss of appetite, bloating, or indigestion; iii. Follow-up of gastric lesions post-endoscopic resection.\n3. Willing to participate voluntarily in the clinical trial and provide written informed consent.\n4. Capable of communicating with researchers and complying with trial requirements.\n\nExclusion criteria\n\n1. Pregnant individuals.\n2. Individuals at high risk of gastrointestinal obstruction, including those identified as being at risk of gastrointestinal stenosis based on the Gastrointestinal Stenosis Assessment Form, those in whom gastrointestinal obstruction cannot be clinically excluded, or individuals with a history of gastrointestinal surgery, severe motor dysfunction, or pseudobulbar palsy.\n3. Individuals with swallowing dysfunction.\n4. Individuals deemed unfit for surgery or unwilling to undergo any surgical procedures.\n5. Participants who are unable to comprehend and\u002For comply with physician instructions during the examination.\n6. Individuals with other medical risks that contraindicate the use of a capsule gastric endoscopy system, or those deemed unsuitable for participation in this study at the discretion of the investigator.",{"count":114,"type":21},482,[116],"NA","The goal of this clinical trial is to evaluate the diagnostic accuracy of the AI-integrated Capsule Gastroscopy (ACG) system in simulated home-use conditions for detecting upper gastrointestinal (UGI) abnormalities. It will also compare the diagnostic accuracy and time efficiency of AI-assisted interpretation versus manual reading of ACG data. The main questions it aims to answer are:\n\nWhat is the diagnostic accuracy of the ACG system, using conventional esophagogastroduodenoscopy (EGD) as a standard of reference?\n\nDoes AI-assisted ACG reading improve diagnostic accuracy or reduce reading time compared to manual ACG video reading?\n\nResearchers will compare ACG results to conventional EGD findings (standard of reference) to determine if ACG can serve as a reliable method for UGI disease detection in home scenarios.\n\nParticipants will:\n\nUndergo an ACG examination in a simulated home environment. Complete an EGD procedure within 24 hours post-ACG ingestion.",[119,91,120,28,31,29],"Gastric Lesion","Upper Gastrointestinal Bleeding (UGIB)",[122,94,95,123,124],"upper gastrointestinal diseases","Diagnostic accuracy","Upper Gastrointestinal abnormalities",{"date":126,"type":43},"2025-07-09",{"date":128,"type":43},"2025-03-03",{"date":130,"type":21},"2026-12-31",{"name":105,"class":50},12,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":84,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":140,"targetDuration":142,"studyType":88,"phases":4,"briefSummary":143,"conditions":144,"keywords":161,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100579293","raman-spectroscopy-based-deep-learning-model-for-early-pan-cancer-early-diagnosis-100579293","NCT06822413","Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","A Novel Raman Spectroscopy-Based Method for Pan-Cancers Early Diagnosis Supported by Deep Learning: A Prospective, Single-Arm, Multicentre Study","Inclusion Criteria:\n\n* Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.\n* Patients in normal physiological conditions without any malignant tumors or precancerous lesions.\n* Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.\n* Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.\n\nExclusion Criteria:\n\n* Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time\n* Post-cancer treatment patients.",{"count":141,"type":21},600,"1 Year","The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are:\n\n* Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk.\n* Identifying which model is more adaptable to the Raman spectrum\n* Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.",[145,146,147,148,149,150,151,152,153,154,155,156,157,158,31,159,160],"Cancer Diagnosis","Liver Cancer, Adult","Cancer Screening","Colorectal Cancer (CRC)","Gastric Cancers","Normal Physiology","Pancreatic Cancer, Adult","Raman Spectroscopy","Deep Learning Model","Esophageal Cancer","Malignant Tumours","Precancerous Conditions","Pancreatitis","Adenoma Colon Polyp","Oesophagitis","Cirrhoses, Liver",[162,163,147,152,164,165,34,154,166,167,157,168,169,159,170],"Pan-cancer","Deep Learning Models","Colorectal Cancer","Pancreatic Cancer","malignant tumour","Precancerous Condtions","Colorectal Adenoma","Gastirc Ulcer","Cirrhoses","2025-04-19",{"date":173,"type":43},"2025-04-24",{"date":175,"type":43},"2022-09-01",{"date":177,"type":21},"2025-07-28",{"name":179,"class":50},"Second Affiliated Hospital, School of Medicine, Zhejiang University",4,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":188,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":51},"100360424","samples-procurement-for-colorectal-cancer-gastric-cancer-and-non-malignant-disease-100360424","NCT03972956","Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease","Samples Procurement for Patients With Colorectal Cancer, Gastric Cancer, and Non-malignant Disease Undergoing Surgery","Inclusion Criteria:\n\n* Any patient diagnosed with colorectal cancer, gastric cancer, non-malignant disease that requires undergoing surgery.\n* Must be willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Subjects whose comorbidities would preclude diagnostic or therapeutic intervention.",{"count":189,"type":21},1000,"The purposes of this study are to collect and store samples including blood, normal and tumor tissue from patients with colorectal cancer or gastric cancer, to collect and store samples including blood and\u002For normal gastrointestinal tissue (if available) from patients with non-malignant disease (including, but not limited to, inflammatory bowel disease (IBD), gastric ulcer, hemorrhoids or hernia), and to create a database for the collected samples and allow access to relevant clinical information for current and future protocols.",[164,34,192,31,193,194],"Inflammatory Bowel Diseases","Hemorrhoids","Hernia","2022-04-28",{"date":197,"type":43},"2022-04-29",{"date":199,"type":43},"2020-12-23",{"date":201,"type":21},"2026-12-23",{"name":203,"class":50},"Renmin Hospital of Wuhan University"]